JCI The Journal of Clinical Investigation

Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL⁺ leukemia cells

Michael G. Kharas, ..., Kevan M. Shokat, David A. Fruman

J Clin Invest. 2017;127(6):2438-2438. https://doi.org/10.1172/JCI95182.

Corrigendum

Original citation: J Clin Invest. 2008;118(9):3038–3050. https://doi.org/10.1172/JCl33337 Citation for this corrigendum: J Clin Invest. 2017;127(6):2438. https://doi.org/10.1172/JCl95182 The authors recently became aware that Figure 7B was not assembled correctly. An incorrect image was included for the β -actin blot. In addition, the blots for 4EBP-1, p-AKT, and total AKT were stretched in the original figure. The authors were able to provide original source data for this figure panel. The correct figure panel, generated from the original source data, is below. The authors regret the errors.

Find the latest version:



Retraction

Equilibrative nucleoside transporter 1 (ENT1) regulates postischemic blood flow during acute kidney injury in mice

Almut Grenz, Jessica D. Bauerle, Julee H. Dalton, Douglas Ridyard, Alexander Badulak, Eunyoung Tak, Eóin N. McNamee, Eric Clambey, Radu Moldovan, German Reyes, Jost Klawitter, Kelly Ambler, Kristann Magee, Uwe Christians, Kelley S. Brodsky, Katya Ravid, Doo-Sup Choi, Jiaming Wen, Dmitriy Lukashev, Michael R. Blackburn, Hartmut Osswald, Imogen R. Coe, Bernd Nürnberg, Volker H. Haase, Yang Xia, Michail Sitkovsky, and Holger K. Eltzschig

Original citation: J Clin Invest. 2012;122(2):693-710. https://doi.org/10.1172/JCI60214.

Citation for this retraction: J Clin Invest. 2017;127(6):2438. https://doi.org/10.1172/JCI94890.

An investigative committee at the University of Colorado Denver recently reported multiple findings of data falsification and fabrication or lack of underlying supporting data regarding Figures 1, 2, 3, 5, 6, 7, 8, and 9, and Supplemental Figures 6 and 8 in this publication. Due to the numerous manipulations and lack of data to support the published findings, the *JCI* is retracting this article.

Corrigendum

 $Ablation \ of \ PI3K \ blocks \ BCR-ABL \ leukemogenesis \ in \ mice, and \ a \ dual \ PI3K/mTOR \ inhibitor \ prevents \ expansion \ of \ human \ BCR-ABL^+ \ leukemia \ cells$

Michael G. Kharas, Matthew R. Janes, Vanessa M. Scarfone, Michael B. Lilly, Zachary A. Knight, Kevan M. Shokat, and David A. Fruman

Original citation: J Clin Invest. 2008;118(9):3038-3050. https://doi.org/10.1172/JCI33337.

Citation for this corrigendum: J Clin Invest. 2017;127(6):2438. https://doi.org/10.1172/JCI95182.

The authors recently became aware that Figure 7B was not assembled correctly. An incorrect image was included for the β -actin blot. In addition, the blots for 4EBP-1, p-AKT, and total AKT were stretched in the original figure. The authors were able to provide original source data for this figure panel. The correct figure panel, generated from the original source data, is below.

The authors regret the errors.

